Secular trends in smoking in relation to prevalent and incident smoking-related disease: A prospective population-based study

INTRODUCTION We examined changes in smoking habits in the general population according to prevalence and incidence of chronic diseases affected by smoking. METHODS We included 12283 individuals enrolled from 2003 in the Copenhagen General Population Study and re-examined from 2014. Participants were classified as either healthy or suffering from chronic obstructive pulmonary disease (COPD), asthma, diabetes mellitus, heart disease or stroke. RESULTS At entry, smoking prevalence was 15.4% in healthy participants, 29.8% with COPD, 15.8% with asthma, 21.7 % with diabetes mellitus, 17.2 % with ischemic heart disease/heart failure and 18.6% in participants with previous stroke. Smoking prevalence declined during the 10 years of observation. Among healthy subjects who developed one of the above mentioned diseases during follow-up, those who developed COPD had the highest initial smoking prevalence (51.5%). Quit rates were highest in those who developed asthma resulting in smoking prevalence of 8.2% versus 27.7% in COPD. After adjustment for age, smoking severity and genotype previously associated with heavy smoking (CHRNA3 rs1051730 AA), significant predictors of quitting were new diagnosis of ischemic heart disease/heart failure (OR=2.33, 95 % CI: 1.61–3.42), new diagnosis of asthma (OR=1.84, 95% CI: 1.18–2.90) and low number of pack-years. CONCLUSIONS Individuals with prevalent smoking related diseases continued to smoke more than healthy individuals. Incident heart disease and asthma, but not incident COPD, stroke or diabetes were associated with a higher chance of quitting. Special focus on smokers with COPD, asthma, diabetes, stroke and ischemic heart disease/heart failure is warranted to decrease smoking prevalence in these groups. Smokers with a new diagnosis of diabetes, stroke and COPD need special smoking cessation support.

[1]  Jongoh Kim,et al.  National Trends in Smoking Cessation Medication Prescriptions for Smokers With Chronic Obstructive Pulmonary Disease in the United States, 2007-2012 , 2018, Journal of preventive medicine and public health = Yebang Uihakhoe chi.

[2]  P. Lange,et al.  Socioeconomic inequality in the use of prescription medications for smoking cessation among patients with COPD: a nationwide study , 2018, International journal of chronic obstructive pulmonary disease.

[3]  C. Janson,et al.  Changes in smoking prevalence and cessation support, and factors associated with successful smoking cessation in Swedish patients with asthma and COPD , 2018, European clinical respiratory journal.

[4]  T. Gislason,et al.  Predictors of smoking cessation: A longitudinal study in a large cohort of smokers. , 2017, Respiratory medicine.

[5]  B. Nordestgaard,et al.  Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. , 2017, The Lancet. Respiratory medicine.

[6]  M. Løchen,et al.  A new diagnosis of asthma or COPD is linked to smoking cessation – the Tromsø study , 2016, International journal of chronic obstructive pulmonary disease.

[7]  M. Hanefeld,et al.  Determinants of mortality in patients with type 2 diabetes: a review , 2016, Reviews in Endocrine and Metabolic Disorders.

[8]  S. Johansson,et al.  O R I G I N a L I N V E S T I G a T I O N Open Access , 2022 .

[9]  R. Peto,et al.  Global effects of smoking, of quitting, and of taxing tobacco. , 2014, The New England journal of medicine.

[10]  Morten Dahl,et al.  Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. , 2012, American journal of respiratory and critical care medicine.

[11]  Nathalie Huguet,et al.  Health behavior change following chronic illness in middle and later life. , 2012, The journals of gerontology. Series B, Psychological sciences and social sciences.

[12]  S. Bojesen,et al.  CHRNA3 genotype, nicotine dependence, lung function and disease in the general population , 2012, European Respiratory Journal.

[13]  S. Rennard,et al.  Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. , 2011, Chest.

[14]  C. Gieger,et al.  Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior , 2010, Nature Genetics.

[15]  Viola Vaccarino,et al.  Predictors of smoking cessation after a myocardial infarction: the role of institutional smoking cessation programs in improving success. , 2008, Archives of internal medicine.

[16]  Daniel F. Gudbjartsson,et al.  A variant associated with nicotine dependence, lung cancer and peripheral arterial disease , 2008, Nature.

[17]  N. Anthonisen,et al.  The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial , 2005 .

[18]  K. J. Macleod,et al.  Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma , 2002, Thorax.